Agios Pharmaceuticals (AGIO) Operating Leases (2019 - 2026)

Agios Pharmaceuticals (AGIO) has 8 years of Operating Leases data on file, last reported at $31.2 million in Q2 2026.

• Quarterly Operating Leases fell 36.07% year-over-year to $31.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $31.2 million (down 36.07% YoY) and the FY2025 annual result came in at $21.8 million, down 45.74% from the prior year.
• Operating Leases eased to $31.2 million in Q2 2026, from $35.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $94.1 million in Q1 2022 to a low of $21.8 million in Q4 2025.
• A 5-year average of $61.6 million and a median of $62.7 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases decreased 8.69% — and 2025, when it tumbled 45.74%.
• Tracing AGIO's Operating Leases over 5 years: stood at $72.0 million in 2022, then slipped by 20.85% to $57.0 million in 2023, then retreated by 29.45% to $40.2 million in 2024, then plunged by 45.74% to $21.8 million in 2025, then surged by 42.89% to $31.2 million in 2026.
• The last three Operating Leases figures came in at $31.2 million (Q2 2026), $35.7 million (Q1 2026), and $21.8 million (Q4 2025), per Business Quant data.